<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="398">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 24, 2013</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01158170</url>
  </required_header>
  <id_info>
    <org_study_id>ZhejiangCH06</org_study_id>
    <nct_id>NCT01158170</nct_id>
  </id_info>
  <brief_title>Prophylactic Cranial Irradiation in Erlotinib/Gefitinib-responders With Non-small Cell Lung Cancer (NSCLC) (RT1001)</brief_title>
  <official_title>A Randomized, Phase III Trial of Prophylactic Cranial Irradiation (PCI) in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Who Are Effective on Erlotinib or Gefitinib(RT1001)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhejiang Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zhejiang Cancer Hospital</source>
  <oversight_info>
    <authority>China: Ethics Committee</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Radiation therapy to the brain may be effective in preventing brain metastases in
      patients with advanced non-small cell lung cancer. It is not yet known whether radiation
      therapy is more effective than observation in patients with advanced non-small cell lung
      cancer.

      PURPOSE: This randomized phase III trial is studying radiation therapy to the brain to see
      how well it works compared with observation in preventing brain metastases in patients with
      advanced non-small cell lung cancer
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

      Determine the effectiveness of prophylactic cranial radiotherapy in patients with advanced
      non-small cell lung cancer that is responsive to gefitinib or erlotinib hydrochloride.

      Secondary

      Determine the progression-free survival in patients treated with this regimen. Determine the
      overall survival in patients treated with this regimen. Determine the safety and
      tolerability of this regimen in these patients. Determine the psycho-neurological effects of
      this regimen in these patients. Determine the quality of life of patients treated with this
      regimen. OUTLINE: This is a multicenter study. Patients with good response( CR/PR) to
      EGFR-TKI(Erlotinib or Gefitinib) are randomized to receive EGFR-TKI plus PCI or EGFR-TKI
      alone,stratified according to prior chemotherapy regimens (first line vs second line), and
      disease response status.

      Group 1: Patients undergo prophylactic brain radiotherapy. Group 2: Patients undergo
      observation. Patients complete quality of life  questionnaires periodically.

      After completion of study therapy, patients are followed up periodically.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2010</start_date>
  <completion_date type="Anticipated">December 2013</completion_date>
  <primary_completion_date type="Anticipated">May 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>The primary endpoint is the cumulative incidence of symptomatic brain metastases (BM)</measure>
    <time_frame>2.5years</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>baseline to date of death from any cause</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>prophylactic cranial irradiation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive Erlotinib or gefitinib until disease progression or intolerable toxicity, and prophylactic cranial irradiation 25GY over 10 fractions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conctrol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients received Erlotinib or gefitinib until disease progression,or intolerable toxicity</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Prophylactic cranial irradiation</intervention_name>
    <description>25GY/10fraction</description>
    <arm_group_label>prophylactic cranial irradiation</arm_group_label>
    <other_name>PCI</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Erlotinib /Gefitinib</intervention_name>
    <description>Erlotinib 150mg/d or Gefitinib 250mg/d until disease progression or intolerable toxicity</description>
    <arm_group_label>prophylactic cranial irradiation</arm_group_label>
    <arm_group_label>Conctrol</arm_group_label>
    <other_name>EGFR-TKI</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients were required to have histologically or cytologically documented

          2. NSCLC and no brain metastasis documented by magnetic resonance imaging (MRI)within 21
             days after confirmed response (RR+SD) to chemotherapy

          3. No previous history of radiotherapy and surgery of brain

          4. good response( CR/PR) to  Erlotinib or Gefitinib.

          5. Agree to radiotherapy

          6. age &gt; 18 and &lt;75 years,ECOG performance status 1 or less

          7. Good renal and hepatic and haematological (absolute neutrophils count 15 x1O9/L and
             platelet count 90 x 109/L,HB&gt;=80g /DL) functions

          8. Have provided informed consent

        Exclusion Criteria:

          1. Seizure cannot be controled by the drugs

          2. Combined with other disease of the brain such as tumour or infarction

          3. Hypersensitivity to MR enhancer  -
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shenglin Ma, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Zhejiang Cancer Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shenglin Ma, MD</last_name>
    <phone>+8657188122568</phone>
    <email>mashenglin@medmail.com.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yaping Xu, MD</last_name>
    <phone>+8657188122082</phone>
    <email>xuyaping1207@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Zhejiang Cancer Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shenglin MA, MD</last_name>
      <phone>+8657188122568</phone>
      <email>mashenglin@medmail.com.cn</email>
    </contact>
    <contact_backup>
      <last_name>Yaping Xu, MD</last_name>
      <phone>+8657188122082</phone>
      <email>xuyaping1207@gmail.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Zhejiang Cancer Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310022</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>XuYa ping, MD</last_name>
      <phone>0086-571-88122082</phone>
      <email>xuyaping1207@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2010</verification_date>
  <lastchanged_date>July 6, 2010</lastchanged_date>
  <firstreceived_date>June 23, 2010</firstreceived_date>
  <responsible_party>
    <name_title>Shenglin Ma</name_title>
    <organization>Zhejiang Cancer Hospital</organization>
  </responsible_party>
  <keyword>nonsmall cell lung cancer</keyword>
  <keyword>brain metastasis</keyword>
  <keyword>prophylactic cranial irradiation</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Gefitinib</mesh_term>
    <mesh_term>Erlotinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
